The JAK1/2 Inhibitor Ruxolitinib Downregulates the Immune Checkpoint Protein B7-H3 in Multiple Myeloma

被引：0
|
作者：
Xu, Ning [1 ]
Ng, Nicole [1 ]
Li, Mingjie [1 ]
Yu, Erin [1 ]
Sanchez, Eric [1 ]
Bujarski, Sean [1 ]
Yin, Zhengyi [1 ]
Hekmati, Tara [1 ]
Field, Dylan [1 ]
Wang, Jasper [1 ]
Nassir, Isabella [1 ]
Yu, Janna [1 ]
Huang, Justin [1 ]
Daniely, David [1 ]
Wang, Cathy S. [1 ]
Chen, Haiming [1 ]
Berenson, James R. [1 ]
机构：
[1] Inst Myeloma Bone Canc Res, West Hollywood, CA USA
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-131047
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1824
引用
收藏
页数：3
相关论文
共 50 条
  • [21] To kill a cancer: Targeting the immune inhibitory checkpoint molecule, B7-H3
    Kanchan, Ranjana K.
    Doss, David
    Khan, Parvez
    Nasser, Mohd. Wasim
    Mahapatra, Sidharth
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2022, 1877 (05):
  • [22] Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy
    Zhao, Binghao
    Li, Huanzhang
    Xia, Yu
    Wang, Yaning
    Wang, Yuekun
    Shi, Yixin
    Xing, Hao
    Qu, Tian
    Wang, Yu
    Ma, Wenbin
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2022, 15 (01)
  • [23] A CASE STUDY OF RESENSITIZATION TO RUXOLITINIB, A JAK1/JAK2 INHIBITOR, IN A PATIENT WITH MYELOFIBROSIS (MF)
    Gisslinger, H.
    Skrabs, C.
    Gisslinger, B.
    Schoder, R.
    Muellauer, L.
    Kralovics, R.
    HAEMATOLOGICA, 2013, 98 : 346 - 347
  • [24] The JAK1/JAK2-inhibitor ruxolitinib inhibits mast cell degranulation and cytokine release
    Hermans, Maud A. W.
    Schrijver, Benjamin
    van Holten-Neelen, Conny C. P. A.
    Gerth van Wijk, Roy
    van Hagen, P. Martin
    van Daele, Paul L. A.
    Dik, Willem A.
    CLINICAL AND EXPERIMENTAL ALLERGY, 2018, 48 (11): : 1412 - 1420
  • [25] Ruxolitinib: An effective JAK1/2 inhibitor in salvage therapy of refractory chronic GVHD
    Simonet, Marion
    Berceanu, Ana
    Daguindau, Etienne
    Desbrosses, Yohan
    Deconinck, Eric
    Larosa, Fabrice
    BONE MARROW TRANSPLANTATION, 2019, 54 : 320 - 320
  • [26] The JAK1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation
    La Rosee, F.
    Bremer, H. -C.
    Hochhaus, A.
    Birndt, S.
    Fellhauer, M.
    Henkes, M.
    Russo, S. G.
    La Rosee, P.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 198 - 198
  • [27] Comparison of the crystal structures of the JAK1/2 inhibitor ruxolitinib and its hydrate and phosphate
    Peng, Ziyu
    Ye, Long
    Acta Crystallographica Section C: Structural Chemistry, 80 : 440 - 447
  • [28] Ruxolitinib: a new JAK1/2 inhibitor that offers promising options for treatment of myelofibrosis
    Ostojic, Alen
    Vrhovac, Radovan
    Verstovsek, Srdan
    FUTURE ONCOLOGY, 2011, 7 (09) : 1035 - 1043
  • [29] Resolution of secondary hemophagocytic lymphohistiocytosis after treatment with the JAK1/2 inhibitor ruxolitinib
    Goldsmith, Scott R.
    Rehman, Sana Saif Ur
    Shirai, Cara L.
    Vij, Kiran
    DiPersio, John F.
    BLOOD ADVANCES, 2019, 3 (23) : 4131 - 4135
  • [30] Comparison of the crystal structures of the JAK1/2 inhibitor ruxolitinib and its hydrate and phosphate
    Peng, Ziyu
    Ye, Long
    ACTA CRYSTALLOGRAPHICA SECTION C-STRUCTURAL CHEMISTRY, 2024, 80 : 440 - +
12345